Abstract:Over the course of the human lifespan, somatic DNA mutations accumulate in healthy tissues. This process has been most clearly described in blood and bone marrow, esophagus, colon and skin, but cumulative DNA damage likely affects all tissues of the body. While most acquired genetic variants have no discernable functional consequences, some randomly occurring somatic mutations confer a relative fitness advantage on a single stem cell and its progeny compared to surrounding cells, which may lead to progressive expansion of a clone (i.e., a genetically identical group of cells). When these mutations occur in a cell with the capacity to self-renew and expand, the mutations persist, and such clonal expansion is a risk factor for further mutation acquisition and clonal evolution.Hematopoietic stem cells are a special case of clonal expansion, because both the stem cells and their blood cell progeny circulate in large numbers, and these cells are not subject to some of the anatomical restrictions that characterize other tissues in which somatic mutations conferring a fitness advantage also occur. Therefore, clonally restricted hematopoiesis can have biological and clinical consequences that are distinct from clonal expansions in other tissues. Such consequences include not just clonal progression to overt myeloid neoplasia (or, less commonly, to lymphoid neoplasia) driven by acquisition of secondary mutations in the cells of the expanded clone, but also cardiovascular events, as described further below – and most likely other diseases that are influenced by aberrant function of mutant blood cells.If we can understand in more detail how clonal hematopoiesis arises and how clonal selection and expansion occur, as well as develop strategies to avert the clinical consequences associated with clonal hematopoiesis, this may both improve public health and yield more general insights into the biology of aging.

Immune-driven clonal cell selection at the intersection among cancer, infectious diseases, autoimmune disorders, and senescence

Clonal evolution and immune evasion in posttransplantation relapses

The senescence journey in cancer immunoediting

Clonal haematopoiesis and dysregulation of the immune system

Immunosenescence: a key player in cancer development

Immune Escape Mechanisms in Non Small Cell Lung Cancer

CD8+ T Cell Senescence: Lights and Shadows in Viral Infections, Autoimmune Disorders and Cancer

Clonal hematopoiesis as a model for premalignant changes during aging

Converging and evolving immuno-genomic routes toward immune escape in breast cancer

Clonal hematopoiesis and autoimmunity

Immunosenescence and cancer: Opportunities and challenges

Immunosenescence: molecular mechanisms and diseases

The Effects of Clonal Heterogeneity on Cancer Immunosurveillance

Mutational landscape of immune surveillance genes in diffuse large B-cell lymphoma

Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade

Immunological hide-and-seek: epigenetically reprogrammed cancer cells and the dynamics of CD8+ T cells

Predictability of B cell clonal persistence and immunosurveillance in breast cancer

Extrinsic and intrinsic drivers of natural killer cell clonality

Immune Escape Mechanisms in Colorectal Cancer Pathogenesis and Liver Metastasis

Decoding Clonal Hematopoiesis: Emerging Themes and Novel Mechanistic Insights

Genomic instability and genetic heterogeneity in aging: insights from clonal hematopoiesis (CHIP), monoclonal gammopathy (MGUS), and monoclonal B-cell lymphocytosis (MBL)